Valuation: The Jenex Corporation

Market Cap 3.06M 2.22M 1.9M 1.78M 1.63M 213M 3.12M 21.07M 8.21M 107M 8.35M 8.17M 353M P/E 2024
-3.25x
P/E 2025 -0.9x
Enterprise Value 3.06M 2.22M 1.9M 1.78M 1.63M 213M 3.12M 21.08M 8.22M 107M 8.35M 8.17M 353M EV / Sales 2024
1,819x
EV / Sales 2025 53.3x
Free-Float
85.95%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 55 2009-09-14
Director of Finance/CFO 40 2023-09-29
Director TitleAgeSince
Chairman 55 2009-11-10
Director/Board Member 78 2018-01-16
Director/Board Member - 2025-10-09
Change 5-day change 1-year change 3-year change Capi.($)
-8.11%-10.53% - - 2.22M
-0.53%+5.33%+28.09%+16.42% 232B
+0.66%+6.46%+5.70%-13.85% 152B
+1.70%-3.74%-19.18%+32.47% 132B
+1.74%-3.64%-52.53%-0.94% 71.55B
+0.35%-1.99%+10.62%+17.62% 51.78B
+0.77%+1.84%-16.23%-11.97% 51.75B
+1.42%+5.64%+33.94%+32.01% 44.14B
+0.50%-2.06%+38.98%+51.09% 39.76B
+0.60%+0.93%+1.67%+7.84% 33.45B
Average -0.10%+0.46%+3.45%+14.52% 89.84B
Weighted average by Cap. +0.58%+1.38%+4.83%+12.29%

Financials

2024 2025
Net sales 6.02K 4.37K 3.74K 3.49K 3.2K 418K 6.13K 41.39K 16.13K 209K 16.4K 16.04K 693K 75.23K 54.62K 46.76K 43.63K 40.03K 5.23M 76.71K 518K 202K 2.62M 205K 201K 8.67M
Net income -2.45M -1.78M -1.52M -1.42M -1.3M -170M -2.5M -16.87M -6.57M -85.34M -6.68M -6.54M -283M -4.34M -3.15M -2.7M -2.52M -2.31M -302M -4.43M -29.88M -11.65M -151M -11.84M -11.58M -501M
Net Debt 64.3K 46.68K 39.97K 37.29K 34.22K 4.47M 65.56K 442K 172K 2.24M 175K 171K 7.41M 1.93K 1.4K 1.2K 1.12K 1.03K 134K 1.96K 13.26K 5.17K 67.09K 5.25K 5.14K 222K
Logo The Jenex Corporation
Therma Bright Inc. is a Canada-based developer and investment partner specializing in advanced diagnostic and medical device technologies that address key healthcare challenges. The Company is developing, acquiring, manufacturing and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace focused on three key strategic areas: respiratory disease, vascular health and consumer medical devices. Its respiratory disease portfolio includes AI4LYF Digital Cough Technology and InStatin-novel inhaled treatment for asthma and COPD. Its vascular disease portfolio includes Inretio-ischemic stroke treatment and Venowave-Deep Vein Thrombosis Treatment Device (DVT). Its consumer health portfolio consists of AcuVid Covid-19 Rapid Antigen Saliva Test, Benepod-Contrast Therapy Device, TheroZAP-Thermal Therapy Device and InterceptCS-Cold Sore Prevention System. The Company holds trademarks for Therozap, InterceptCS and AcuVid.
Employees
-